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Abstract
The additive Alterion NE® is a preparation containing viable spores of a strain of Bacillus subtilis. The
additive is intended for use in feed for chickens for fattening and chickens reared for laying at the
proposed dose of 1 9 108 CFU/kg complete feedingstuffs. B. subtilis is considered by EFSA to be
suitable for the qualiﬁed presumption of safety approach to establish safety. As the identity of the active
agent was established and the lack of toxigenic potential and of resistance to antibiotics of human or
veterinary clinical signiﬁcance demonstrated, the additive is presumed safe for the target species,
consumers and the environment. Alterion NE® is not a dermal irritant but is irritant to eyes and should be
considered a potential respiratory sensitiser. In the absence of data, no conclusion can be drawn on the
dermal sensitisation of the additive. Alterion NE® at the recommended dose 1 9 108 CFU/kg feed has
the potential to improve the zootechnical performance of chickens for fattening. This conclusion can be
extended to chickens reared for laying when used at the same dose. B. subtilis DSM 29784 is compatible
with monensin sodium, narasin/nicarbazin, salinomycin sodium, lasalocid sodium, diclazuril, narasin,
maduramicin ammonium, robenidine hydrochloride and decoquinate at the highest authorised levels.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from ADISSEO France SAS2 for authorisation of the
product Alterion NE® (Bacillus subtilis DSM 29784), when used as a feed additive for chickens for
fattening (category: zootechnical additives; functional group: gut ﬂora stabilisers). During the
assessment, the applicant requested a change in the species by adding chickens reared for laying.
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). The particulars and documents in
support of the application were considered valid by EFSA as of 5 October 2016.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Alterion NE® (Bacillus subtilis DSM 29784) when used under the proposed conditions of use
(see Section 3.1.4).
1.2. Additional information
The additive Alterion NE® is a preparation containing viable spores of Bacillus subtilis DSM 29784.
It has not been previously authorised as a feed additive in the EU.
The bacterial species B. subtilis is considered by EFSA to be suitable for the qualiﬁed presumption
of safety (QPS) approach to safety assessment (EFSA, 2007; EFSA BIOHAZ Panel, 2017). This
approach requires the identity of the strain to be conclusively established and evidence that the strain
lacks of toxigenic potential and does not show resistance to antibiotics of human and veterinary
importance.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier3 in support of the authorisation request for the use of Alterion NE® (Bacillus subtilis DSM 29784)
as a feed additive. The technical dossier was prepared following the provisions of Article 7 of Regulation
(EC) No 1831/2003, Regulation (EC) No 429/20084 and the applicable EFSA guidance documents.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of the active agent in animal feed. The Executive Summary of the EURL
report can be found in Annex A.5
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Alterion NE® is
in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant guidance
documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012a) Technical guidance on
tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Guidance on studies
concerning the safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012b), Guidance
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 ADISSEO France SAS, Immeuble Anthony Parc II, 10 place du general de Gaulle 92160, Antony, France.
3 FEED dossier reference: FAD-2016-0040.
4 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
5 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/ﬁnrep-fad-2016-0040_alterionne.pdf
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on the assessment of the toxigenic potential of Bacillus species used in animal nutrition (EFSA FEEDAP
Panel, 2014), Technical guidance on the update of the criteria used in the assessment of bacterial
resistance to antibiotics of human or veterinary importance (EFSA FEEDAP Panel, 2012c) and Technical
guidance – Compatibility of zootechnical microbial additives with other additives showing antimicrobial
activity (EFSA, 2008).
3. Assessment
The additive Alterion NE® is a preparation of B. subtilis DSM 29784 intended for use in feed for
chickens for fattening and chickens reared for laying (category: zootechnical additives; functional
group: gut ﬂora stabilisers) to improve the performance of chickens.
3.1. Characterisation
3.1.1. Characterisation of active agent
The B. subtilis strain was originally isolated from soil and has not been genetically modiﬁed.6 The
strain has been deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen with the
accession number DSM 29784.7
Taxonomical identiﬁcation is based on the sequencing of the full 16S rRNA gene.8 A 99.9% sequence
similarity was demonstrated with other B. subtilis 16S rRNA genes in the consulted databases, which
conﬁrms the identity of the strain as B. subtilis. This was conﬁrmed by the sequencing of the partial gyrB
gene (1,200 bp). Genetic stability of the strain was conﬁrmed by means of pulse ﬁeld gel electrophoresis
of the genomic restriction fragments.9 Using this method, the master culture was compared with several
generations of growth. No differences in the resultant patterns were observed.
Cytotoxicity of the strain was assessed on Vero cells using the culture supernatants in accordance
to the FEEDAP Panel guidance document (EFSA FEEDAP Panel, 2014).10 No detectable lysis of a Vero
cell culture was detected upon exposure to culture supernatant from B. subtilis DSM 29784.
Consequently, the strain is not considered toxigenic.
B. subtilis DSM 29784 was tested for antibiotic susceptibility using broth microdilution.11 The
battery of antibiotics tested was that recommended by EFSA (EFSA FEEDAP Panel, 2012c). All
minimum inhibitory concentration (MIC) values were below the corresponding cut-off values deﬁned by
the FEEDAP Panel. Therefore, the strain is considered susceptible to all relevant antibiotics.
3.1.2. Characterisation of the additive12
The manufacturing process of the additive is detailed in the dossier. The additive has a ﬁnal
minimum guaranteed concentration of 1 9 1010 CFU of B. subtilis DSM 29784 per gram of additive.
Batch-to-batch variation was measured in ﬁve batches of the additive and found to be compliant
with speciﬁcations (mean value: 1.7 9 1010 CFU/g, range: 1.5–1.9 9 1010 CFU/g).13
All batches are routinely tested for microbiological contaminants (i.e. Enterobacteriaceae,
Escherichia coli, yeasts and ﬁlamentous fungi and Salmonella) and the Hazard Analysis and Control of
Critical Points (HACCP) plan foresees monitoring for chemical impurities (i.e. heavy metals, arsenic,
aﬂatoxin, dioxins and total polychlorinated biphenyls (PCBs)). Analysis of four batches of the additive
revealed that the levels of heavy metals (Pb ≤ 1.16 mg/kg, Hg < 0.01 mg/kg and Cd ≤ 0.16 mg/kg),
arsenic (≤ 0.53 mg/kg), aﬂatoxin B1 (< 0.1 lg/kg), dioxins (sum of polychlorinated dibenzoparadioxins
(PCDDs) and polychlorinated dibenzofurans (PCDFs) = 0.13 ng WHO-PCDD/F-TEQ per kg), total
dioxins (sum of PCDDs and PCDFs and PCBs = 0.19 ng WHO-PCDD/F-PCB-TEQ per kg),
Enterobacteriaceae (< 10 CFU/g), E. coli (< 10 CFU/g), yeasts and ﬁlamentous fungi (< 20 CFU/g) and
6 Technical dossier/Section II/Annex II.2.2.
7 Technical dossier/Section II/Annex II.2.1.
8 Technical dossier/Section II/Annex II.2.3 and Supplementary information February 2017/Annex II.1.1.
9 Technical dossier/Section II/Annex II.2.4.
10 Technical dossier/Section II/Annex II.2.5.
11 Technical dossier/Section II/Annex II.2.6 and Supplementary information February 2017.
12 This section has been amended following the conﬁdentiality claims made by the applicant.
13 Technical dossier/Section II/Annex II.1.3.
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Salmonella (absent in 25 g), do not give raise to concerns.14,15 An analysis of three further batches
conﬁrmed the absence of B. cereus contamination (< 100 CFU/g).16
The product is a granular free-ﬂowing powder. Four batches were examined for particle size
distribution by laser diffraction and dusting potential with a Stauber–Heubach dustometer.17 Results
showed that 1.1% by volume of the additive consists of particles with diameters below 50 lm and that
there are no particles with a diameter below 10 lm. The mean value for dusting potential was 0.06 g/m3.
3.1.3. Stability and homogeneity
Shelf-life of three batches of Alterion NE® stored in its original packaging was examined at three
conditions (25°C/60% relative humidity (RH), 30°C/65% RH and 40°C/75% RH).18 Bacilli counts
remained constant (losses < 0.5 log) at 40°C up to 6 months and at 25°C and 30°C up to 10 months,
the last time points measured.
Stability of three batches of Alterion NE® was examined when incorporated (at 0.2%) in a
minerals/vitamins premixture (containing choline chloride) and stored for 8 months at two conditions
(25°C and 30°C) in sealed high-density polyethylene pouches.19 Bacilli counts of two batches showed
no variation overtime while the third batch showed a gradual loss of viability (0.5 log units at
8 months).
The stability of one batch of Alterion NE® to pelleting conditions (82, 88 and 93°C for 45 s) was
tested when mixed at the proposed inclusion level with chickens’ feed.20 The enumeration of bacilli
showed a recovery higher than 100% at all pelleting conditions. In a different study, the bacilli counts
of three batches after a pelleting at 70°C showed a recovery close to 90% after the thermal treatment.
In the same study, stability of the additive (three batches) was tested when incorporated in mash
and pelleted feed for chickens at the proposed dose and stored for 4 months at 25°C/RH 60% and
30°C/RH 65%.21 No differences were seen in bacilli counts at the end of the storage period.
To test the capacity of Alterion NE® to be homogeneously incorporated in three batches of
premixtures and mash and pelleted feed (one batch each), 10 subsamples were collected from the
materials prepared in the tests described above.22 Bacilli counts showed a coefﬁcient of variation of
5–7% for the premixtures and pelleted feed and of 21% for the mash feed.
3.1.4. Conditions of use
The additive is intended for use in feed for chickens for fattening and chickens reared for laying at
the minimum recommended dose of 1 9 108 CFU/kg feedingstuffs.
The additive is intended for use in the presence of the permitted coccidiostats: lasalocid sodium,
robenidine hydrochloride, maduramicin ammonium, decoquinate, salinomycin sodium, monensin
sodium, narasin, diclazuril and narasin/nicarbazin.
3.2. Safety
3.2.1. Safety for the target species, consumers and environment
In the view of the FEEDAP Panel, the identity of the active agent is established as B. subtilis and
the toxigenic potential and the antibiotic resistance qualiﬁcations have been met. Therefore, based on
the QPS approach to safety assessment, B. subtilis DSM 29784 is presumed safe for the target
species, consumer of products from animals fed with the additive and the environment. No concerns
are expected from other excipients present in the product, so Alterion NE® is also considered safe for
target animals, consumers and the environment.
14 Limits of quantiﬁcation: Pb = 0.02 mg/kg, Hg = 0.01 mg/kg, Cd = 0.01 mg/kg, arsenic = 0.1 mg/kg, aﬂatoxin
B1 = 0.0001 mg/kg, dioxins = 0.13 ng WHO-PCDD/F-TEQ per kg, total PCBs 0.19 ng WHO-PCDD/F-TEQ per kg,
Enterobacteriaceae = 10 CFU/g, E. coli (< LOQ), yeasts and ﬁlamentous fungi = 20 CFU/g.
15 Technical dossier/Section II/Annex II.1.5.
16 Technical dossier/Supplementary information February 2017/Annex II.3.1.
17 Technical dossier/Section II/Annexes II.1.10-11.
18 Technical dossier/Section II/Annex II.4.1.
19 Technical dossier/Section II/Annex II.4.2.
20 Technical dossier/Section II/Annex II.4.4.
21 Technical dossier/Section II/Annex II.4.3.
22 Technical dossier/Section II/Annexes II.4.2-3.
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3.2.2. Safety for the user
A small fraction of the particles (1.1%) has a diameter below 50 lm. Although the dusting potential
is low, there is a potential exposure of the upper respiratory tract of people handling the product.
Given the proteinaceous nature of the active agent, the additive should be considered to be a potential
respiratory sensitiser.
The dermal irritation/corrosion potential of Alterion NE® was tested in an in vitro test
(reconstructed human epidermis test according to the OECD guideline 439).23 The mean viability of
the skin membranes was 87% compared to the negative control group. Based on these results,
Alterion NE® is non-irritant to skin.
The eye irritation/corrosion potential of Alterion NE® was tested with the in vitro isolated chicken
eye test according to the OECD guideline 438.24 Alterion NE® caused corneal effects consisting of
slight corneal swelling or slight to moderate opacity and very slight or slight ﬂuorescein retention.22
Based on the results obtained in the present study, Alterion NE® is irritating to eyes.
In the absence of data, no conclusion can be drawn on the dermal sensitisation properties of the
additive.
3.2.2.1. Conclusions on safety for the user
Alterion NE® is not a dermal irritant but is irritant to eyes and should be considered a potential
respiratory sensitiser. In the absence of data, no conclusion can be drawn on the dermal sensitisation
of the additive.
3.3. Efﬁcacy
3.3.1. Efﬁcacy for chickens for fattening
Four ﬂoor pen studies were performed in two Member States and in two extra European countries
(respecting European farming conditions) to demonstrate the efﬁcacy of Alterion NE® in chickens for
fattening.
The design of the studies is presented in Table 1 and the results in Table 2. In all cases, 1-day-old
birds (male in studies in studies 1,25 226 and 4,27 and the same number of males and females in study
328) were allocated in randomised complete blocks to two treatment groups: a control group receiving
a basal diet and a treatment group receiving the same basal diet supplemented with the additive at
the recommended dose of 1 9 108 CFU/kg complete feedingstuffs (concentration was conﬁrmed by
analysis of feed). Each dietary treatment was replicated as shown in Table 1. The diets were offered to
the animals ad libitum. Health status was monitored throughout the experimental periods. Feed intake
and body weight of the animals were measured and feed to gain ratio was calculated. Data were
analysed in a randomised complete block design with the birds being blocked by initial body weight at
day 0. Performance data were subjected to an analysis of variance (ANOVA). The model included the
diet and block as main factor in studies 1, 2 and 4 and the diet, gender and block as main factors, and
interaction diet 9 gender in study 3. The experimental unit was the pen for all parameters. Data on
mortality were analysed with Chi-square test.
23 Technical dossier/Section III/Annex III.2.
24 Technical dossier/Section III/Annex III.3.
25 Technical dossier/Section IV/Annex 3.1 and Supplementary information/Annex 6.1 and 6.2.
26 Technical dossier/Section IV/Annex 3.2 and Supplementary information/Annex 6.3 and 6.4.
27 Technical dossier/Section IV/Annex 3.3 and Supplementary information/Annex 6.5 and 6.6.
28 Technical dossier/Section IV/Annex 3.4 and Supplementary information/Annex 6.7 and 6.8.
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Supplementation of Alterion NE® increased the ﬁnal weight and weight gain of birds in two studies.
Feed to gain ratio of birds receiving Alterion NE® was signiﬁcantly improved compared to control birds
in all four trials.
3.3.2. Efﬁcacy for chickens reared for laying
The efﬁcacy of Alterion NE® for chickens for fattening has been established. Since the mechanism
of action of the additive can be reasonably assumed to be same, the above conclusions reached in
chickens for fattening can be extended to chickens reared for laying.
3.3.2.1. Conclusions on efﬁcacy for the target species
Alterion NE® at the recommended dose 1 9 108 CFU/kg feed has the potential to improve the
zootechnical performance of chickens for fattening. This conclusion can be extended to chickens
reared for laying when used at the same dose.
3.3.3. Compatibility with coccidiostats
An in vivo study was conducted to establish compatibility of B. subtilis DSM 29784 with lasalocid
sodium, robenidine hydrochloride, maduramicin ammonium, decoquinate, salinomycin sodium,
monensin sodium, narasin, diclazuril and narasin/nicarbazin.29 The study involved 900 one-day-old
male chickens (Ross 308) randomly allocated to 10 treatments, each replicated nine times and with
ten birds per replicate. The treatments were:
Table 1: Details on the study design for the studies performed in chickens for fattening
Study no
Duration of
the study
(days)
Breed
(sex)
Total animals
replicates/
treatment 3 animals/
replicate
Alterion NE®
(CFU/kg
feed)
Basal diets
(main ingredients)
form
1 35 Ross PM3
♂
390
13 9 15
0
1 9 108
Starter and grower
(maize/soybean meal)
pelleted
2 42 Cobb 500
♂
1,040
13 9 40
0
1 9 108
Starter and grower/ﬁnisher
(wheat/maize/soybean meal)
pelleted
3 35 Cobb 500
♀,♂
960
40(a) 9 12
0
1 9 108
Starter, grower and ﬁnisher
(maize/soybean meal)
pelleted
4 42 Cobb 500
♂
1,600
20 9 40
0
1 9 108
Starter, grower and ﬁnisher
(maize/soybean meal)
pelleted
CFU: colony forming unit.
(a): 20 pens of females and 20 pens of males.
Table 2: Summary of the overall performance results of the trials made with chickens for fattening
Study no
Alterion NE®
(CFU/kg feed)
Feed intake
(kg)
Final weight
(kg)
Weight gain
(kg/bird)
Feed:gain Mortality (%)
1 0 3.66 2.29b 2.25b 1.63a 4.1
1 9 108 3.76 2.43a 2.39a 1.58b 2.6
2 0 4.83a 2.78 2.74 1.77a 5.2
1 9 108 4.75b 2.81 2.77 1.71b 4.2
3 0 2.98a 1.94 1.90 1.56a 0.4
1 9 108 2.87b 1.96 1.92 1.49b 0.6
4 0 3.57 1.95b 1.91b 1.87a 2.4
1 9 108 3.57 2.06a 2.02a 1.77b 3.6
a,b: Means in a column within a given trial with different superscript letters are signiﬁcantly different p < 0.05.
29 Technical dossier/Section II/Annex II.4.5.
Alterion NE® for chickens for fattening and reared for laying
www.efsa.europa.eu/efsajournal 8 EFSA Journal 2017;15(7):4933
• T1: Control (Alterion NE® at 1 9 108 CFU/kg feed – no coccidiostat)
• T2: Alterion NE® at 1 9 108 CFU/kg feed + monensin sodium at 125 mg/kg feed
• T3: Alterion NE® at 1 9 108 CFU/kg feed + narasin/nicarbazin at 50/50 mg/kg feed
• T4: Alterion NE® at 1 9 108 CFU/kg feed + salinomycin sodium at 70 mg/kg feed
• T5: Alterion NE® at 1 9 108 CFU/kg feed + lasalocid A sodium at 125 mg/kg feed
• T6: Alterion NE® at 1 9 108 CFU/kg feed + diclazuril at 1 mg/kg feed
• T7: Alterion NE® at 1 9 108 CFU/kg feed + narasin at 70 mg/kg feed
• T8: Alterion NE® at 1 9 108 CFU/kg feed + maduramicin ammonium at 6 mg/kg feed
• T9: Alterion NE® at 1 9 108 CFU/kg feed + robenidine hydrochloride at 36 mg/kg feed
• T10: Alterion NE® at 1 9 108 CFU/kg feed + decoquinate at 40 mg/kg feed
Concentration in feed was conﬁrmed by analysis. The trial lasted 42 days during which birds were
followed for weight gain, feed intake and mortality. Average daily gain (ADG) and feed to gain ratio
were calculated. At the end of the experiment, 100 animals (10/treatment group) were killed and ileal
and caecal digesta samples collected and analysed for Bacillus counts, with and without heat
treatment in order to differentiate between the vegetative cells and spores.
The data on ﬁnal weight, body weight gain, feed intake and feed to gain ratio were analysed with
ANOVA. The model included the diet as main factor. The B. subtilis counts on ileal and caecal samples
were analysed using the Dunnett T-test for paired comparison with the control. The pen was the
experimental unit for all parameters. The results are given in Table 3.
No signiﬁcant differences were observed on any of the performance parameters measured.
Mortality was low (3.7% on average) and not inﬂuenced by treatment.
There were no signiﬁcant differences between the control and any of the treated groups in Bacillus
counts.
3.3.3.1. Conclusions on compatibility with coccidiostats
B. subtilis DSM 29784 is compatible with monensin sodium, narasin/nicarbazin, salinomycin sodium,
lasalocid sodium, diclazuril, narasin, maduramicin ammonium, robenidine hydrochloride and
decoquinate at the highest authorised levels.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation30 and Good
Manufacturing Practice.
Table 3: Ileal and caecal Bacillus subtilis counts from chickens for fattening treated with the
additive and different coccidiostats
Treatment
Log CFU Bacillus subtilis/g ileum
content
Log CFU Bacillus subtilis/g caecum
content
 Heat treatment + Heat treatment  Heat treatment + Heat treatment
Control 4.8 4.8 4.6 4.7
Monensin sodium 4.7 4.7 4.4 4.5
Narasin/nicarbazin 4.7 4.7 4.5 4.6
Salinomycin sodium 4.6 4.6 4.4 4.4
Lasalocid A sodium 4.8 4.8 4.6 4.5
Diclazuril 4.7 4.6 4.4 4.4
Narasin 4.8 4.8 4.4 4.4
Maduramicin ammonium 4.7 4.7 4.6 4.7
Robenidine hydrochloride 4.6 4.6 4.6 4.6
Decoquinate 4.6 4.7 4.4 4.5
CFU: colony forming unit.
30 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
Alterion NE® for chickens for fattening and reared for laying
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2017;15(7):4933
4. Conclusions
The active agent fulﬁls the requirements of the QPS approach to the assessment of safety and no
concerns are expected from other components of the additive. Consequently, Alterion NE® can be
presumed safe for the target species, consumers of products derived from animals fed the additive
and the environment.
Alterion NE® is not a dermal irritant but is irritant to eyes and should be considered a potential
respiratory sensitiser. In the absence of data, no conclusion can be drawn on the dermal sensitisation
of the additive.
Alterion NE® at the recommended dose 1 9 108 CFU/kg feed has the potential to improve the
zootechnical performance of chickens for fattening. This conclusion can be extended to chickens
reared for laying when used at the same dose.
B. subtilis DSM 29784 is compatible with the coccidiostats monensin sodium, narasin/nicarbazin,
salinomycin sodium, lasalocid sodium, diclazuril, narasin, maduramicin ammonium, robenidine
hydrochloride and decoquinate at the highest authorised levels.
Documentation provided to EFSA
1) Alterion NE® for chickens for fattening. June 2016. Submitted by ADISSEO France S.A.S.
2) Alterion NE® for chickens for fattening. Supplementary information. February 2017.
Submitted by ADISSEO France S.A.S.
3) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods(s) of Analysis for Alterion NE®.
4) Comments from Member States.
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ADG average daily gain
ANOVA analysis of variance
CFU colony-forming unit
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DSM Deutsche Sammlung von Mikroorganismen und Zellkulturen
EURL European Union Reference Laboratory
HACCP Hazard Analysis and Control of Critical Points
LOQ limit of quantiﬁcation
MIC minimum inhibitory concentration
PCBs polychlorinated biphenyls
PCDDs polychlorinated dibenzoparadioxins
PCDFs polychlorinated dibenzofurans
QPS qualiﬁed presumption of safety
RH relative humidity
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Appendix A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Methods of Analysis
for Alterion NE®
In the current application authorisation is sought under Article 4(1) for Bacillus subtilis DSM 29784
under the category/functional group 4(b) ‘zootechnical additives’/‘gut ﬂora stabilisers’, according to
Annex I of Regulation (EC) No 1831/2003. Speciﬁcally, authorisation is sought for the use of the feed
additive for chickens for fattening.
According to the Applicant, the feed additive contains as active substance viable spores of non-
genetically modiﬁed Bacillus subtilis DSM 29784. The feed additive is to be marketed as light brown to
brown granular free ﬂowing powder, containing a minimum Bacillus subtilis DSM 29784 content of
1 9 1010 colony forming units per gram of feed additive (CFU/g). The feed additive is intended to be
used directly in feedingstuffs or through premixtures at a minimum dose of 1 9 108 CFU/kg of
complete feedingstuffs.
For the identiﬁcation of Bacillus subtilis DSM 29784 the EURL recommends for ofﬁcial control Pulsed
Field Gel Electrophoresis (PFGE), a generally recognised standard methodology for genetic
identiﬁcation. This standard methodology for microbial identiﬁcation is currently being evaluated by the
CEN Technical Committee 327 to become a European Standard.
For the enumeration of Bacillus subtilis DSM 29784 in feed additive, premixtures and feedingstuffs
the Applicant submitted the ring-trial validated spread plate method EN 15784 which was already
evaluated by EURL in the frame of previous bacilli dossiers. Based on the performance characteristics
available, the EURL recommends for ofﬁcial control the CEN method for the enumeration of
Bacillus subtilis DSM 29784 in the three matrices.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
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